KDM5B and melanoma: Interestingly, KDM5B overexpression reprogrammed melanoma cells to a CD34−, more drug-tolerant, phenotype, while KDM5B loss shifted melanoma cells to a more BRAFi-responsive CD34+ state, potentiating the pivotal role of KDM5A in modulating intratumoral heterogeneity in CM [78].